Remaining challenges in clinical translation, production standardization, and large-scale quality assurance are highlighted
Researchers should first define their primary hypothesis, considering whether they want to focus on appetite/satiety mechanisms (Cagrilintide) or broader metabolic and energy expenditure effects (Survodutide)
Where Not to Inject GHK-Cu Do not inject into skin that is red, swollen, bruised, scarred, tender, infected, lumpy, hardened, or numb
Choose injectable BPC-157 if: Your target is a tendon, ligament, joint, or muscle injury You need systemic anti-inflammatory or tissue repair effects Speed and reliability of delivery matter You are working within a structured peptide therapy protocol with a licensed provider Choose oral BPC-157 if: Your primary concern is gut health leaky gut, IBD, IBS, gastric ulcers You want high local GI concentrations, not systemic distribution You prefer non-invasive administration for long-term or maintenance use You are combining BPC-157 with another systemic peptide therapy Consider nasal delivery only if: Neurological applications are the clinical focus A licensed provider explicitly recommends it based on your presentation Injection is contraindicated and oral delivery is insufficient Do not choose a delivery method based on convenience alone
doi: 10.1038/s41435-023-00235-6
Nofal et al., 2024), and acting as biostimulants, promoting seed germination, plant growth, and resilience to stressors (Drocco et al., 2024